AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

IGM Biosciences Inc. (IGMS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.41

-0.11 (-7.24%)

At close: Feb 20, 2025, 3:59 PM

1.44

2.13%

After-hours: Feb 20, 2025, 05:48 PM EST

undefined% (undefined)

Bid	1.35
Market Cap	83.84M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.61
PE Ratio (ttm)	-0.39
Forward PE	n/a
Analyst	Hold

Ask	1.53
Volume	160,639
Avg. Volume (20D)	480,167
Open	1.55
Previous Close	1.52
Day's Range	1.39 - 1.55
52-Week Range	1.26 - 22.50
Beta	undefined

About IGMS

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinica...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 18, 2019

Employees 198

Stock Exchange NASDAQ

Ticker Symbol IGMS

Website https://igmbio.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for IGMS stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 41.84% from the latest price.

Buy 12.50%

Hold 87.50%

Sell 0.00%

Stock Forecasts

Next Earnings Release

IGM Biosciences Inc. is scheduled to release its earnings on Mar 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-66.29%

IGM Biosciences shares are trading lower after the... Unlock content with Pro Subscription

2 months ago

+8.99%

IGM Biosciences shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating on the stock and announced a price target of $21.

News

2 weeks ago · zacks.com

Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround

IGM Biosciences (IGMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in re...

2 weeks ago · accessnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are adv...

1 month ago · accessnewswire.com

IGMS STOCK ALERT: Levi & Korsinsky Notifies IGM Biosciences, Inc. Investors of an Ongoing Investigation

NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of IGM Biosciences, Inc. ("IGM Biosciences, Inc.") (NASDAQ:IGMS) concerni...

1 month ago · https://thefly.com

IGM Biosciences downgraded to Hold from Buy at Stifel

Stifel downgraded IGM Biosciences to Hold from Buy with a price target of $2.50, down from $27. Th firm cites the company's "surprising decision" to discontinue all further development of its autoimmu...

1 month ago · https://thefly.com

IGM Biosciences downgraded to Underweight from Equal Weight at Morgan Stanley

Morgan Stanley analyst Michael Ulz downgraded IGM Biosciences to Underweight from Equal Weight with a price target of $2, down from $12. The company announced discontinuation of its autoimmune program...

1 month ago · https://thefly.com

IGM Biosciences downgraded to Market Perform from Outperform at BMO Capital

BMO Capital downgraded IGM Biosciences to Market Perform from Outperform with a price target of $2, down from $21, following the company's strategic update, which included discontinuation of imvotamab...

1 month ago · marketwatch.com

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.